- Home
- GGB vs IONS Comparison
GGB vs IONS Comparison
Compare GGB & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGB
- IONS
- Stock Information
- Founded
- GGB 1901
- IONS 1989
- Country
- GGB Brazil
- IONS United States
- Employees
- GGB N/A
- IONS N/A
- Industry
- GGB Steel/Iron Ore
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- GGB Industrials
- IONS Health Care
- Exchange
- GGB Nasdaq
- IONS Nasdaq
- Market Cap
- GGB 5.5B
- IONS 4.6B
- IPO Year
- GGB 1999
- IONS 1991
- Fundamental
- Price
- GGB $2.67
- IONS $29.70
- Analyst Decision
- GGB Buy
- IONS Buy
- Analyst Count
- GGB 2
- IONS 18
- Target Price
- GGB $5.00
- IONS $57.00
- AVG Volume (30 Days)
- GGB 11.4M
- IONS 1.9M
- Earning Date
- GGB 04-28-2025
- IONS 04-30-2025
- Dividend Yield
- GGB 5.28%
- IONS N/A
- EPS Growth
- GGB N/A
- IONS N/A
- EPS
- GGB 0.35
- IONS N/A
- Revenue
- GGB $10,837,144,685.00
- IONS $705,138,000.00
- Revenue This Year
- GGB $8.01
- IONS N/A
- Revenue Next Year
- GGB $4.95
- IONS $25.80
- P/E Ratio
- GGB $7.35
- IONS N/A
- Revenue Growth
- GGB N/A
- IONS N/A
- 52 Week Low
- GGB $2.27
- IONS $23.95
- 52 Week High
- GGB $4.04
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- GGB 49.73
- IONS 51.27
- Support Level
- GGB $2.49
- IONS $28.79
- Resistance Level
- GGB $2.69
- IONS $30.12
- Average True Range (ATR)
- GGB 0.12
- IONS 1.55
- MACD
- GGB 0.02
- IONS 0.36
- Stochastic Oscillator
- GGB 94.05
- IONS 93.19
About GGB Gerdau S.A.
Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutor, mechanical construction bars, reinforced steel locks. The company's geographical segment includes Brazil Operations; North America Operations; South America Operations as well as Special Steel Operations. It derives majority of the revenue from the North America Operations segment.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.